Leerink raises ARS Pharmaceuticals stock price target on sales expansion

ARS Pharmaceuticals reported Q4 2025 U.S. net product revenue for neffy of $20.3M and total Q4 revenue of $28.1M (vs $26.9M est, +4.5%), with FY2025 revenue $72.2M roughly in line with a $73M consensus and EPS of -$0.41 (beat vs -$0.4246 est). The company ended 2025 with approximately $245M cash (management expects this to fund operations to cash-flow break-even) and is expanding its salesforce from 106 to 150 reps while tightening account management and scaling a virtual prescribing platform. Regulatory progress includes neffy approvals in China and Australia (Dec 2025), a positive CHMP opinion for EURneffy (Jan 2026), and expected Canadian approval in Q2 2026; payer access talks are advancing with potential CVS Caremark formulary addition by July 1 and ongoing discussions with Anthem and Aetna. Analysts maintain a Strong Buy consensus with price targets $12–$35 and InvestingPro forecasts ~92% revenue growth for 2026, supporting upside but offset by notes on cash burn.

Analysis

Expanding a field sales footprint while keeping SG&A neutral is a tactical lever that often shifts marginal dollars from broad marketing to higher-frequency, higher-yield prescribers; expect incremental prescription growth to be concentrated in the top decile practices and a slowdown in low-ROI account activity. That concentration raises two second-order dynamics: (1) larger customers gain negotiating leverage with PBMs/insurers because volume is more fungible, and (2) the company’s unit economics will become more sensitive to rebate pressure and patient assistance costs, meaning headline market share gains could underdeliver on cash conversion.

Scaling a direct-to-prescriber virtual platform changes the channel mix and patient acquisition curve—digital-origin scripts typically have faster time-to-first-fill but lower switching friction, which is positive for adoption velocity yet increases churn and reduces sample-driven loyalty. International regulatory wins broaden optionality but import pricing-reference and tender dynamics that typically compress launch-year realized prices versus U.S. levels; management will need to manage a bifurcated margin profile between North America and ROW markets.

The pacing of payer formulary decisions and interim clinical readouts constitutes the dominant near-term binary risk set over the next 3–9 months. If coverage expansions hit as hoped, upside is quick but likely to be partially offset by rebate-driven net price erosion; conversely, any unexpected PBM exclusions or a slower uptake in digital prescribing could force incremental promotional spend or extended cash burn. From a positioning perspective, asymmetric payoff structures (options, spreads, pairs) are preferable to naked exposures given the binary nature of payer outcomes and potential short-term volatility.

Key Decisions for Investors

• Initiate a tactical long: SPRY 12-month call spread (buy 1x near-term OTM call, sell 1x further OTM call) sized to 1–2% of portfolio — target 2.5x return if positive payer decisions and favorable uptake occur; max loss = premium paid. Timeframe: 6–12 months to capture formulary cadence and digital channel scaling.
• Event-driven pair: long SPRY equity (small position, e.g., 1–1.5% portfolio) funded by short position in a large incumbent epinephrine/auto-injector maker (select a large cap peer) — idea captures asymmetric growth vs incumbent complacency if new channel adoption accelerates. Hold 3–9 months, stop-loss at 20% on the net pair position.
• Yield-enhancing collar: buy SPRY shares and sell near-term covered calls while buying protective puts 6–9 months out to cap downside from a payer setback yet retain upside to a successful coverage expansion. Use size to limit capital at risk to no more than 2% of NAV.
• Short tail-risk via options: buy 6–9 month puts (modest size) to hedge against the binary risk of payer exclusion or negative interim trial readout; cost is insurance against a sharp re-rating event. Trim or sell as we get positive PBM decisions.
• Monitor catalyst triggers (PBM/formulary decisions, interim clinical readout) and be ready to scale to a larger long within 30 days post-confirmation — take profits incrementally once 50%+ of expected coverage uplift is reflected in realized net price and scripts.